To the full analysis
Buyback calculator for WuXi Biologics (Cayman)
WuXi Biologics (Cayman) stock: dividend
2269.HKWuXi Biologics (Cayman) does not currently pay a dividend. From fiscal 2023 to 2025, WuXi Biologics (Cayman) bought back its own shares for $632.72M.
Whether WuXi Biologics (Cayman) Inc. pays a dividend and what the company does with its cash instead: free cash flow, buybacks of its own shares and the share count over recent years.
Daily figure as of 13 Nov 2026
Free cash flow and buybacks
| Fiscal year | Free cash flow | Share buybacks | Shares outstanding |
|---|---|---|---|
| 2025 | $419.71M | $230.39M | 4.18B |
| 2024 | $193.1M | $264.83M | 4.08B |
| 2023 | $65.56M | $137.5M | 4.16B |
| 2022 | −$49M | $420.57M | 4.17B |
| 2021 | −$463.67M | $377.48M | 4.40B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.